{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T12:29:35Z","timestamp":1775219375450,"version":"3.50.1"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Uncontrolled oxidative stress contributes to the pathogenesis of inflammatory bowel disease (IBD), yet its association with disease activity and response to biological therapy, has never been studied in saliva. We investigated whether salivary oxidative stress markers could predict therapeutic response to biologics in IBD patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Seventy-three IBD patients (46 ulcerative colitis (UC), 27 Crohn\u2019s disease (CD)) eligible for infliximab or vedolizumab and 56 healthy controls (HC) were enrolled. Salivary advanced oxidation protein products (AOPPs), advanced glycated end-products (AGEs), and ferric reducing antioxidant power (FRAS) were measured at baseline and at week 26. Clinical response was assessed at weeks 26 and 52, and endoscopic activity at baseline and week 52.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Baseline AOPPs and AGEs were higher in IBD than HC (p &amp;lt; 0.0001), but only AOPPs distinguished mild from moderate-severe endoscopic activity (AUC 0.72; p &amp;lt; 0.05). Clinical response at week 26 was 77.8% in CD and 69.6% in UC, yet AOPPs remained stable from baseline. Endoscopic remission at week 52 occurred in 40.7% of CD and 23.9% of UC patients. Neither baseline nor 26-week AOPPs or AGEs predicted endoscopic improvement or remission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Salivary AOPPs reflect baseline disease severity but do not predict response to biologics. Persistent AOPPs accumulation despite clinical control suggests a decoupling between clinical remission and oxidative homeostasis. Understanding the drivers and clinical relevance of persistent AOPPs is needed before considering potential therapeutic applications, such as antioxidant-based adjunctive strategies or interventions targeting AOPP-mediated damage, to improve remission rates in IBD patients receiving advanced treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1699252","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T05:21:23Z","timestamp":1762492883000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Salivary oxidative stress persists in inflammatory bowel disease regardless of biological treatment response"],"prefix":"10.3389","volume":"16","author":[{"given":"Elisabetta","family":"Bigagli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tommaso","family":"Innocenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Dragoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Pindozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Galli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maura","family":"Lodovici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Luceri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1010853","DOI":"10.3389\/fcimb.2022.1010853","article-title":"The oral-gut axis: salivary and fecal microbiome dysbiosis in patients with inflammatory bowel disease","volume":"12","author":"Abdelbary","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1053\/j.gastro.2024.06.036","article-title":"It's time to change tack in IBD treatment","volume":"167","author":"Behr","year":"2024","journal-title":"Gastroenterology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1006\/abio.1996.0292","article-title":"The ferric reducing ability of plasma (FRAP) as a measure of \u201cantioxidant power\u201d: the FRAP assay","volume":"239","author":"Benzie","year":"1996","journal-title":"Anal. Biochem."},{"key":"B4","doi-asserted-by":"publisher","first-page":"882","DOI":"10.3390\/nu15040882","article-title":"Impact of preoperative immunonutrition on oxidative stress and gut barrier function in surgical patients with crohn's disease","volume":"15","author":"Bigagli","year":"2023","journal-title":"Nutrients"},{"key":"B5","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3389\/fphys.2019.00499","article-title":"Crohn's disease in clinical remission is marked by systemic oxidative stress","volume":"10","author":"Bourgonje","year":"2019","journal-title":"Front. Physiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.molmed.2020.06.006","article-title":"Oxidative stress and redox-modulating therapeutics in inflammatory bowel disease","volume":"26","author":"Bourgonje","year":"2020","journal-title":"Trends Mol. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.crohns.2013.01.010","article-title":"The burden of inflammatory bowel disease in Europe","volume":"7","author":"Burisch","year":"2013","journal-title":"J. Crohns Colitis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"620124","DOI":"10.3389\/fimmu.2021.620124","article-title":"The \u201cGum-Gut\u201d axis in inflammatory bowel diseases: a hypothesis-driven review of associations and advances","volume":"12","author":"Byrd","year":"2021","journal-title":"Front. Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.bbadis.2004.02.008","article-title":"Biochemical and spectrophotometric significance of advanced oxidized protein products","volume":"1689","author":"Capeill\u00e8re-Blandin","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e007397","DOI":"10.1161\/JAHA.117.007397","article-title":"Circulating concentrations of redox biomarkers do not improve the prediction of adverse cardiovascular events in patients with type 2 diabetes mellitus","volume":"7","author":"Cournot","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"B11","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/s0016-5107(04)01878-4","article-title":"Development and validation of a new, simplified endoscopic activity score for crohn's disease: the SES-CD","volume":"60","author":"Daperno","year":"2004","journal-title":"Gastrointest. Endosc."},{"key":"B12","doi-asserted-by":"publisher","first-page":"19198","DOI":"10.1038\/s41598-023-46714-8","article-title":"Deciphering salivary microbiome signature in crohn's disease patients with different factors contributing to dysbiosis","volume":"13","author":"Elzayat","year":"2023","journal-title":"Sci. Rep."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.3748\/wjg.14.2851","article-title":"N-acetyl-L-cysteine combined with mesalamine in the treatment of ulcerative colitis: randomized, placebo-controlled pilot study","volume":"14","author":"Guijarro","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/s0140-6736(80)92767-1","article-title":"A simple index of crohn's disease activity","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1136\/gutjnl-2024-334346","article-title":"DUOX2 activation drives bacterial translocation and subclinical inflammation in IBD-Associated dysbiosis","volume":"74","author":"Hazime","year":"2025","journal-title":"Gut"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1007\/s10620-004-9564-5","article-title":"Alterations in antioxidant power and levels of epidermal growth factor and nitric oxide in saliva of patients with inflammatory bowel diseases","volume":"49","author":"Jahanshahi","year":"2004","journal-title":"Dig. Dis. Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/odi.13537","article-title":"Salivary changes in oxidative stress related to inflammation in oral and gastrointestinal diseases","volume":"27","author":"Jan\u0161\u00e1kov\u00e1","year":"2021","journal-title":"Oral Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1111\/apt.18218","article-title":"The contribution of dietary advanced glycation end-products and genetic risk in the development of inflammatory bowel disease: a prospective cohort study","volume":"60","author":"Jiang","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/ibd.20383","article-title":"Enhanced formation of advanced oxidation protein products in IBD","volume":"14","author":"Krzystek-Korpacka","year":"2008","journal-title":"Inflamm. Bowel Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.3390\/biomedicines11051388","article-title":"The influence of gut microbiota on oxidative stress and the immune system","volume":"11","author":"Kunst","year":"2023","journal-title":"Biomedicines"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.cgh.2015.02.019","article-title":"Curcumin in combination with mesalamine induces remission in patients with mild-to-moderate ulcerative colitis in a randomized controlled trial","volume":"13","author":"Lang","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3390\/antiox11010138","article-title":"Nutritional regimes enriched with antioxidants as an efficient adjuvant for IBD patients under infliximab administration: a pilot study","volume":"11","author":"Liso","year":"2022","journal-title":"Antioxidants (Basel)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"378","DOI":"10.3390\/antiox8090378","article-title":"Analysis of oxidative stress-related markers in crohn's disease patients at surgery and correlations with clinical findings","volume":"8","author":"Luceri","year":"2019","journal-title":"Antioxidants (Basel)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1390351","DOI":"10.3389\/fendo.2024.1390351","article-title":"The emerging role of oxidative stress in inflammatory bowel disease","volume":"15","author":"Muro","year":"2024","journal-title":"Front. Endocrinol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3390\/nu15020405","article-title":"Advanced glycation end-products and their effects on gut health","volume":"15","author":"Phuong-Nguyen","year":"2023","journal-title":"Nutrients"},{"key":"B26","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s10620-021-06837-2","article-title":"New insights into the role of oral microbiota dysbiosis in the pathogenesis of inflammatory bowel disease","volume":"67","author":"Qi","year":"2022","journal-title":"Dig. Dis. Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1053\/j.gastro.2021.09.078","article-title":"Breaking through the therapeutic ceiling: what will it take?","volume":"162","author":"Raine","year":"2022","journal-title":"Gastroenterology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1196\/annals.1378.060","article-title":"Alterations in salivary antioxidants, nitric oxide, and transforming growth factor-beta 1 in relation to disease activity in crohn's disease patients","volume":"1091","author":"Rezaie","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/0016-5085(90)90613-6","article-title":"Predictability of the postoperative course of crohn's disease","volume":"99","author":"Rutgeerts","year":"1990","journal-title":"Gastroenterology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study","volume":"317","author":"Schroeder","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"101196","DOI":"10.1016\/j.redox.2019.101196","article-title":"Advanced oxidation protein products induce G1 phase arrest in intestinal epithelial cells via a RAGE\/CD36-JNK-p27kip1 mediated pathway","volume":"25","author":"Shi","year":"2019","journal-title":"Redox Biol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"107312","DOI":"10.1016\/j.isci.2023.107312","article-title":"Advanced oxidation protein products induce paneth cells defects by endoplasmic reticulum stress in crohn's disease","volume":"26","author":"Shi","year":"2023","journal-title":"iScience"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41368-022-00209-w","article-title":"Promising applications of human-derived saliva biomarker testing in clinical diagnostics","volume":"15","author":"Song","year":"2023","journal-title":"Int. J. Oral Sci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"362","DOI":"10.20452\/pamw.4273","article-title":"Markers of lipid peroxidation and antioxidant status in the serum and saliva of patients with active crohn disease","volume":"128","author":"Szczeklik","year":"2018","journal-title":"Pol. Arch. Intern. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"103380","DOI":"10.1016\/j.redox.2024.103380","article-title":"Oxidative stress-related biomarkers as promising indicators of inflammatory bowel disease activity: a systematic review and meta-analysis","volume":"77","author":"Traten\u0161ek","year":"2024","journal-title":"Redox Biol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1093\/ecco-jcc\/jjz208","article-title":"Riboflavin supplementation in patients with crohn's disease (the RISE-UP study)","volume":"14","author":"von Martels","year":"2020","journal-title":"J. Crohns Colitis"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1430001","DOI":"10.3389\/fimmu.2024.1430001","article-title":"The oral-gut microbiome axis in inflammatory bowel disease: from inside to insight","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Immunol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/ki.1996.186","article-title":"Advanced oxidation protein products as a novel marker of oxidative stress in uremia","volume":"49","author":"Witko-Sarsat","year":"1996","journal-title":"Kidney Int."},{"key":"B42","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41392-024-02094-7","article-title":"Low-input redoxomics facilitates global identification of metabolic regulators of oxidative stress in the gut","volume":"10","author":"Xiao","year":"2025","journal-title":"Signal. Transduct. Target Ther."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e1006","DOI":"10.1038\/cddis.2013.542","article-title":"Advanced oxidation protein products induce intestine epithelial cell death through a redox-dependent, c-jun N-terminal kinase and poly (ADP-ribose) polymerase-1-mediated pathway","volume":"5","author":"Xie","year":"2014","journal-title":"Cell Death Dis."},{"key":"B40","doi-asserted-by":"publisher","first-page":"103963","DOI":"10.1016\/j.numecd.2025.103963","article-title":"Sex-specific optimal cut-off points for metabolic health indicators to predict incident type 2 diabetes mellitus","volume":"35","author":"Xing","year":"2025","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1089\/ars.2015.6611","article-title":"Advanced oxidation protein products induce epithelial-mesenchymal transition of intestinal epithelial cells via a PKC\u03b4-mediated, redox-dependent signaling pathway","volume":"27","author":"Xu","year":"2017","journal-title":"Antioxid. Redox Signal."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1699252\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T05:21:24Z","timestamp":1762492884000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1699252\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":42,"alternative-id":["10.3389\/fphar.2025.1699252"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1699252","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"article-number":"1699252"}}